Reminder Bell Improves Incentive Spirometer Use After CABG

By David Douglas

April 19, 2019

NEW YORK (Reuters Health) - Following coronary artery bypass grafting (CABG) surgery, compliance with incentive spirometer use was improved by the SpiroTimer, an add-on use tracking device that sounds a reminder bell, researchers say.

In an April 10 online paper in JAMA Surgery, Dr. Adam E. M. Eltorai of Brown University, Providence, Rhode Island, and colleagues note that to reduce atelectasis, incentive spirometers work to open alveoli through sustained maximal inspiration.

The approach is routinely prescribed, they say, but "its effectiveness has yet to be demonstrated, largely because of the inability to reliably track use adherence."

In a randomized trial, 160 patients undergoing CABG had SpiroTimers attached to their spirometers. They were randomized to "bell on" or control "bell off" groups. The baseline medical and motivation-to-recover characteristics of the two groups were similar, although the control group had more smokers.

In the bell-on group, the bell sounded every hour (the clinically suggested use frequency) to remind patients to employ the device. To avoid sleep disruption, the SpiroTimer was turned on each morning and continued to record use until bedtime between 8 and 9 pm. The standard nursing incentive spirometer orders were to simply remind patients every four hours to use the device.

In total, 145 patients completed the study per protocol. The mean number of daily inspiratory breaths was 35.4 in the bell-on group compared to 17.1 in the bell- off control group. The percentage of recorded hours with at least one or more inspiratory breaths was also more than doubled in the intervention group (58.2% versus 27.5%). There were no differences between those undergoing elective and nonelective surgery.

In patients undergoing nonelective procedures, bell on reduced the median postoperative length of stay (6 days versus 7 days) and intensive care unit stay (3 days versus 4 days). Also, the mean atelectasis severity scores for the final chest radiographs before discharge were significantly lower for the bell-on than bell-off group. The bell-on group mortality at 6 months was zero compared to 9% in controls.

The researchers conclude, "With the reminder, incentive spirometry appears to be clinically effective when used appropriately."

In an editorial, Dr. Danny Chu and colleagues at the University of Pittsburgh School of Medicine, note that the SpiroTimer "does seem to improve compliance with a therapy that many believe decreases respiratory complications and promotes rehabilitation and discharge following any operation."

However, they go on to say, "the remainder of the study does require caution when interpreting the claimed improvement in outcomes."

For example, "A variable that deserves attention was the significantly increased history of smoking in the control arm, which as a single factor may predict a more difficult postoperative respiratory recovery."

The authors, they conclude "are to be congratulated for developing a device for easily measuring and increasing adherence to incentive spirometer performance. However, we believe that larger clinical trials that are powered to detect important clinically significant end points between well-balanced groups will be required to determine if the cost and use of such a device is justified."

Commenting by email, Dr. Davide Cattano of the University of Texas Health Science Center at Houston told Reuters Health that incentive spirometry "has been confronted by mixed evidence of effectiveness: in my opinion it is a great tool for pulmonary rehabilitation, even if it can be surpassed by other techniques, it is cheap and available... at the bedside."

Dr. Cattano, a professor of anesthesiology who has conducted research in the field, noted that there is an ongoing need for pulmonary rehabilitation to be utilized. Incentive spirometry, he concluded, "is a first line. Assisted (spirometry) may even be more effective. Pathways to increase adherence and effective performance need to be investigated."

Drs. Eltorai and Chu did not respond to requests for comments.

SOURCE: http://bit.ly/2VS1vC1 and http://bit.ly/2VOUCBG

JAMA Surgery 2019.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....